scholarly journals EP 2 and EP 4 receptor antagonists: Impact on cytokine production and β 2 ‐adrenergic receptor desensitization in human airway smooth muscle

2018 ◽  
Vol 234 (7) ◽  
pp. 11070-11077 ◽  
Author(s):  
Peta Bradbury ◽  
Nowshin N. Rumzhum ◽  
Alaina J. Ammit
Keyword(s):  
Smooth Muscle ◽  
Airway Smooth Muscle ◽  
Adrenergic Receptor ◽  
Cytokine Production ◽  
Receptor Desensitization ◽  
Human Airway Smooth Muscle ◽  
Receptor Antagonists ◽  
Human Airway

scholarly journals Polymorphism of the β2-Adrenergic Receptor Gene and Desensitization in Human Airway Smooth Muscle

2000 ◽  
Vol 162 (6) ◽  
pp. 2117-2124 ◽  
Author(s):  
PAUL E. MOORE ◽  
JOHANNE D. LAPORTE ◽  
JOSEPH H. ABRAHAM ◽  
IGOR N. SCHWARTZMAN ◽  
CHANDRI N. YANDAVA ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Airway Smooth Muscle ◽  
Adrenergic Receptor ◽  
Receptor Gene ◽  
Human Airway Smooth Muscle ◽  
Human Airway ◽  
Β2 Adrenergic Receptor ◽  
Adrenergic Receptor Gene

Modulation of epidermal growth factor receptor binding to human airway smooth muscle cells by glucocorticoids and β2-adrenergic receptor agonists

2009 ◽  
Vol 296 (4) ◽  
pp. L693-L699 ◽  
Author(s):  
Karen M. Kassel ◽  
Nancy A. Schulte ◽  
Myron L. Toews
Keyword(s):  
Smooth Muscle ◽  
Airway Smooth Muscle ◽  
Adrenergic Receptor ◽  
Lung Fibroblasts ◽  
Airway Smooth Muscle Cells ◽  
Protein Synthesis Inhibitor ◽  
Egf Receptors ◽  
Human Airway Smooth Muscle ◽  
Synthesis Inhibitor ◽  
Human Airway

EGF receptors (EGFRs) are increased in airway smooth muscle in asthma, which may contribute to both their hyperproliferation and hypercontractility. Lysophosphatidic acid (LPA) is a candidate pathological agent in asthma and other airway diseases, and LPA upregulates EGFRs in human airway smooth muscle (HASM) cells. We tested whether therapeutic glucocorticoids and/or β2-adrenergic receptor (β2AR) agonists also alter EGFR binding in HASM cells. Exposure to glucocorticoids for 24 h induced a twofold increase in EGFR binding similar to that with LPA; fluticasone was markedly more potent than dexamethasone. The increase in EGFR binding by glucocorticoids required 24-h exposure, consistent with transcription-mediated effects. Although the increase in EGFR binding was blocked by the protein synthesis inhibitor cycloheximide for LPA, fluticasone, and dexamethasone, only LPA induced a significant increase in EGFR protein expression detected by immunoblotting. In contrast to the increased binding induced by the glucocorticoids, the β2AR agonists isoproterenol, albuterol, and salmeterol all induced a decrease in EGFR binding. β2AR agonist effects were multiphasic, with an initial decline at 2–4 h that reversed by 6 h and a second, somewhat greater decrease by 18–24 h. In cells pretreated with glucocorticoids, the decreases in EGFR binding by subsequent β2AR treatment were not statistically significant; glucocorticoid upregulation of EGFRs also prevented further increases by LPA. Similar increases by glucocorticoids and decreases by β2AR agonists were found in HFL-1 human lung fibroblasts. These complex and opposing effects of clinically relevant glucocorticoids and β2AR agonists on airway mesenchymal cell EGFRs likely contribute to their overall therapeutic profile in the diseased airway.

scholarly journals Dexamethasone rescues TGF-β1-mediated β2-adrenergic receptor dysfunction and attenuates phosphodiesterase 4D expression in human airway smooth muscle cells

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Elena Chung ◽  
Christie A. Ojiaku ◽  
Gaoyuan Cao ◽  
Vishal Parikh ◽  
Brian Deeney ◽  
...  
Keyword(s):  
Gene Expression ◽  
Smooth Muscle ◽  
Airway Smooth Muscle ◽  
Adrenergic Receptor ◽  
Airway Smooth Muscle Cells ◽  
Human Airway Smooth Muscle ◽  
Human Airway ◽  
Phosphodiesterase 4D ◽  
Camp Levels ◽  
Tgf Β1

Abstract Glucocorticoids (GCs) and β2-adrenergic receptor (β2AR) agonists improve asthma outcomes in most patients. GCs also modulate gene expression in human airway smooth muscle (HASM), thereby attenuating airway inflammation and airway hyperresponsiveness that define asthma. Our previous studies showed that the pro-fibrotic cytokine, transforming growth factor- β1 (TGF-β1) increases phosphodiesterase 4D (PDE4D) expression that attenuates agonist-induced levels of intracellular cAMP. Decreased cAMP levels then diminishes β2 agonist-induced airway relaxation. In the current study, we investigated whether glucocorticoids reverse TGF-β1-effects on β2-agonist-induced bronchodilation and modulate pde4d gene expression in HASM. Dexamethasone (DEX) reversed TGF-β1 effects on cAMP levels induced by isoproterenol (ISO). TGF-β1 also attenuated G protein-dependent responses to cholera toxin (CTX), a Gαs stimulator downstream from the β2AR receptor. Previously, we demonstrated that TGF-β1 treatment increased β2AR phosphorylation to induce hyporesponsiveness to a β2 agonist. Our current data shows that expression of grk2/3, kinases associated with attenuation of β2AR function, are not altered with TGF-β1 stimulation. Interestingly, DEX also attenuated TGF-β1-induced pde4d gene expression. These data suggest that steroids may be an effective therapy for treatment of asthma patients whose disease is primarily driven by elevated TGF-β1 levels.

Sign in / Sign up

Export Citation Format

Share Document